EcoDrugPlus

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSLACG00000012034
Gene Symbol: ATP4B
4 Cross references
184 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSLACG00000001454
Gene Symbol: ATP1A1
3 Cross references
322 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 2

Ensembl ID : ENSLACG00000000476
Gene Symbol: ATP1A2
4 Cross references
208 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 3

Ensembl ID : ENSLACG00000012768
Gene Symbol: ATP1A3
3 Cross references
135 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSLACG00000014205
Gene Symbol: ATP1B1
4 Cross references
296 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSLACG00000005279
Gene Symbol: ATP1B3
4 Cross references
299 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSLACG00000009886
Gene Symbol: ATR
3 Cross references
206 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSLACG00000017950
Gene Symbol: AXL
4 Cross references
197 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSLACG00000011252
Gene Symbol: BRAF
2 Cross references
220 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSLACG00000009939
Gene Symbol: BCL2L1
2 Cross references
289 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSLACG00000009379
Gene Symbol: BCL2L10
4 Cross references
129 Possible Orthologues:

Bcl2 Like 2

Ensembl ID : ENSLACG00000005987
Gene Symbol: BCL2L2
4 Cross references
64 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).